EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 11 April 2024

EFPIA responds to the European Parliament plenary vote: Despite improvements, the Pharmaceutical Legislation has a long way to go to restore Europe’s competitive edge

EFPIA responds to the European Parliament plenary vote.

Ensuring patients have faster, more equitable access to new medicines - and how Europe can close the investment gap on other parts of the world - has been the subject of significant debate in the past months.

We believe that the Parliament has voted through certain amendments that have enhanced the European Commission’s original proposals. A move welcomed by industry.

Despite some improvement, the EP position reduces regulatory data protection by six months. It is difficult to understand how reducing incentives to research, develop and manufacture new medicines and vaccines could ever be in the best interest of Europe or European patients.

EFPIA response to the European Parliament endorsement of the political agreement on UWWT directive...
11 April 2024

We support the overall objective of the revision to address water pollution, but we believe that every stakeholder must... Read more

Life science industry concerns over the workability of EU HTA: Europe cannot miss out on the...
09 April 2024

We urge the Member States’ representatives to take into account these serious concerns from the innovative life science... Read more

Data driven life course immunisation: What are we waiting for?

Save the Date | 23 April, 14:00 - 15:45 CEST

Against the backdrop of the Belgian Presidency and critical negotiations on the European Health Data Space, we're bringing together vaccine experts, scientists, and policymakers to explore how the EU can unlock the full potential of health data and electronic immunisation registries toward improved vaccination coverage.

Register here.

Towards a European Cardiovascular Health Plan

Sixty million people live with cardiovascular disease in Europe, making it the biggest killer in our Union.

Watch Manfred Weber, EPP President, discuss the disparities, challenges and opportunities in tackling cardiovascular disease across the EU. He is joined by the European Society of Cardiology President, Franz Weidinger.

Events

The Impact of the Pharma Directive on the European Life Science Industry
16 April 2024 (Brussels)

How can the revision of the Pharmaceutical Legislation enhance the competitiveness and appeal of the EU pharmaceutical... Read more

Rare Diseases Forum: Securing Europe’s competitiveness in R&D for people living with rare diseases...
16 April 2024 (Brussels)

Join to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. Read more

What we are reading

1000 Organisations United Call On EU Leaders To Support The Business Case For Investing In...
On 11 April 2024 (Cefic)

Brussels, 11 April 2024: The Antwerp Declaration, and its call for a European Industrial Deal, has seen a remarkable... Read more

Limited innovation and profitability driving slow motion AMR crisis, Piot calls for action
On 04 April 2024 (Euractiv)

Professor Peter Piot, Belgium’s special advisor to European Commission president Ursula von der Leyen for European... Read more

Inclusivity, transparency, delivery – navigating the EU’s new Health Technology Assessment...
On 21 March 2024 (Euractiv)

The EFPIA HTA Working Group’s Inka Heikkinen and James Ryan spoke with Euractiv’s Nicole Verbeeck, giving insights... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu